The clinician pulled up an anatomy poster on the consult room wall. Two structures highlighted in different colors. The iliac crest at the back of the pelvis, marked with a small cross where the harvest needle would enter. The abdominal subcutaneous fat layer, marked with a different cross at the flank. Two harvest sites, two source tissues, two procedures the patient was being asked to choose between for the same target joint. The patient had committed to autologous cell therapy. The remaining question was which source.
Bone marrow and adipose tissue are the two most clinically common autologous sources for stem cell therapy in 2026. Both contain mesenchymal stem or stromal cells. Both have published research bases for orthopedic applications. The two are not identical, and the difference between them affects yield, harvest experience, response patterns, and the specific applications where each shows the stronger comparative profile.
Where the Two Most Common Adult Stem Cell Sources Originate
Bone marrow is the soft tissue inside the spongy bone of the iliac crest, sternum, and other large bones. The harvest target in clinical practice is almost always the iliac crest at the back of the pelvis, where the bone marrow is accessible through a needle inserted under local anesthesia. The aspirate that comes back contains a mixed cellular population: hematopoietic stem cells, mesenchymal stem cells, progenitor cells, and supporting cell types. The mesenchymal fraction relevant to orthopedic regenerative therapy is a small percentage of the total cells in the aspirate, requiring concentration through centrifugation to produce the bone marrow concentrate the patient receives.
Adipose tissue is the subcutaneous fat layer accessible at the abdomen, flank, or other body sites. The harvest is a small lipoaspiration, similar in technique to a small-volume cosmetic liposuction but performed for cellular harvest rather than fat removal. The lipoaspirate contains adipose-derived stem cells (also called adipose-derived stromal cells or ADSCs) at substantially higher density than the bone marrow mesenchymal fraction. After processing, the cellular product can be reinjected at the target tissue.
The published literature on NIH PubMed Central documents that both populations meet the ISCT minimal criteria for mesenchymal stromal cells, with surface marker profiles that overlap substantially while showing source-specific differences in functional assays.
How Cell Yield and Concentration Differ Between Sources
The yield difference between the two sources is one of the most consistently reported findings in the comparative literature. Adipose tissue produces a substantially higher cell yield per unit volume of harvest tissue, with some published comparisons reporting yields several hundred-fold higher for adipose-derived stem cells per gram of tissue compared to mesenchymal cells per milliliter of bone marrow aspirate.
A short comparison the patient can carry:
| Dimension | Bone marrow | Adipose |
|---|---|---|
| Cell density per harvest volume | Lower | Higher |
| Total cells per typical harvest | Variable, depends on aspirate volume | Generally higher per equivalent harvest volume |
| Concentration step required | Yes, centrifugation | Yes, processing including digestion or mechanical separation |
| In vitro proliferation rate | Lower than adipose | Higher |
| Senescence onset in culture | Earlier than adipose | Later |
The patient implication is that adipose harvest may produce a larger cellular dose with less harvest volume, while bone marrow harvest may require higher aspirate volumes to reach comparable cell counts. The clinical relevance of this difference depends on the specific procedure protocol, target dose, and clinical setting.
Harvest Procedure: How Each Source Is Collected
Procedure day differs between the two harvests in ways the patient should know to expect:
Bone marrow harvest from iliac crest
- Local anesthesia at the harvest site, sometimes combined with sedation depending on clinic protocol
- Patient positioned prone or laterally to access the back of the pelvis
- Needle insertion through skin and into the marrow space, with aspiration into a syringe
- Sometimes performed at multiple aspirate sites within the same procedure to reach target volume
- Procedure time generally 20 to 40 minutes for the harvest itself
- Post-harvest soreness at the iliac crest site for several days, with bruising in some patients
Adipose harvest from abdomen or flank
- Local anesthesia, typically tumescent infiltration of the harvest site
- Patient positioned to access the abdominal or flank fat layer
- Small lipoaspiration cannula inserted through a small skin entry point
- Aspirated lipoaspirate collected for processing
- Procedure time generally 30 to 60 minutes for the harvest itself
- Post-harvest soreness, mild bruising, and minor cosmetic change at the harvest site possible
Patients who have had previous procedures at one or the other site may have a strong preference based on prior experience. Patients with no prior preference often find the adipose harvest more comfortable in the moment but report comparable post-procedure soreness profiles.
Why Clinical Applications Favor One Source Over Another
The comparative research base shapes which source is preferred for which application. The patterns are not absolute, and individual clinic experience varies, but several themes recur:
- For orthopedic and cartilage applications, bone marrow concentrate has the longer clinical track record and the stronger published evidence base in the United States. The chondrogenic differentiation potential of bone marrow mesenchymal cells is reported as higher than adipose-derived cells in many in vitro comparison studies.
- For larger volume cell needs and applications where cell yield matters more than chondrogenic specificity, adipose-derived cells offer practical advantages. Several recent meta-analyses, including comparisons in knee osteoarthritis, have found favorable response patterns for adipose-derived cells.
- For applications outside orthopedics (cardiovascular, neurological, certain immune-mediated conditions), the published clinical research volume is much heavier on the bone marrow side, which reflects historical research focus rather than necessarily a definitive efficacy difference.
The comparative literature does not yet support a categorical “one is better than the other” conclusion. Different applications, different patient profiles, and different clinic protocols can reasonably favor either source. The patient’s question is less about which is universally better and more about which fits the specific procedure the patient is considering.
What Patients Experience During Bone Marrow vs. Adipose Harvest
The patient experience during the harvest itself differs in ways patients describe consistently across clinic practices.
Bone marrow harvest produces a distinctive sensation as the needle enters the marrow space, sometimes described as a deep pressure or pulling. The local anesthesia controls the surface pain. The deep aspiration sensation persists through the harvest itself. Patients with a low pain tolerance for procedural sensations sometimes report the bone marrow harvest as the more uncomfortable of the two. Clinics often offer additional sedation for patients who request it.
Adipose harvest produces a different sensation profile. The tumescent anesthesia substantially reduces sensation at the harvest site. The lipoaspiration itself feels like a steady tugging or pulling on the abdominal or flank tissue. Patients generally describe the experience as uncomfortable but not painful, with the discomfort resolving as the procedure ends. The harvest site shows bruising for several days after the procedure, which patients should expect.
Neither harvest is a major procedure in clinical terms. Both are outpatient. Both allow same-day discharge. The patient walks out of the clinic with a small bandage at the harvest site and another at the injection site, in either case.
Which Source the Current Research Suggests for Specific Applications
A short reference for the patient working through the source decision in the consultation:
| Application | Source where current research is stronger |
|---|---|
| Knee osteoarthritis (mild to moderate) | Both have evidence; recent meta-analyses favor adipose for some response measures |
| Cartilage repair specifically | Bone marrow concentrate, based on chondrogenic potential |
| Tendon and rotator cuff applications | Both, with bone marrow longer track record |
| Spinal applications | Bone marrow concentrate, where research base is more established |
| Cardiovascular and neurological (research stage) | Bone marrow, by published research volume |
| Cosmetic and dermatological | Adipose-derived cells, where yield advantage matters |
The ISCT MSC committee position, in its current nomenclature and characterization guidance, treats source-specific properties as relevant rather than incidental, recommending that MSCs be referenced together with their tissue source rather than as a uniform category. The AAOS OrthoInfo resource on stem cell use in orthopaedics treats both bone marrow concentrate and adipose-derived cells as part of the broader regenerative options under active research, without endorsing one over the other for routine orthopedic care.
The clinician at the anatomy poster ends the consult by asking which procedure aligns better with the patient’s specific joint, weighed against the clinic’s documented experience with each protocol. The cross marks on the poster have stayed in the same anatomical positions since the start of the appointment. The decision the patient leaves with often tends to come from a careful read of which source the published research supports for the specific application alongside what the patient is willing to experience during the harvest.
Important note on regenerative therapy: No regenerative therapy is fully predictable in outcome, and any guidance that promises otherwise overstates what current evidence supports. The realistic question for a patient considering treatment is what level of preliminary or emerging evidence the patient and clinician find sufficient and what specific practices keep the decision aligned with that evidence base.
Sources:
- Comparative Analysis of Human Mesenchymal Stem Cells from Bone Marrow and Adipose Tissue, NIH PubMed Central
- International Society for Cell and Gene Therapy, MSC Committee Position Statements on Nomenclature and Tissue Sources, Cytotherapy
- Use of Stem Cells in Orthopaedics, OrthoInfo, American Academy of Orthopaedic Surgeons